دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The International Brain Initiative: collaboration in progress
doi : 10.1016/S1474-4422(21)00384-7
Volume 20, Issue 12, December 2021, Page 969
Erythropoietin and optic neuritis in the TONE study
FionaCostelloa
doi : 10.1016/S1474-4422(21)00378-1
Volume 20, Issue 12, December 2021, Pages 970-971
Paediatric multiple sclerosis: a lesson from TERIKIDS
Maria PiaSormaniabEmmanuelleWaubantc
doi : 10.1016/S1474-4422(21)00372-0
Volume 20, Issue 12, December 2021, Pages 971-973
New therapies for Pompe disease: are we closer to a cure?
RosaPuertollanoaNinaRabena
doi : 10.1016/S1474-4422(21)00358-6
Volume 20, Issue 12, December 2021, Pages 973-975
Amantadine: an old drug reborn
RajeshPahwaa
doi : 10.1016/S1474-4422(21)00356-2
Volume 20, Issue 12, December 2021, Pages 975-977
20th Anniversary photography competition: neurology for zoomers
ElenaBecker-BarrosoaLauraHartaHeatherBrownaSarahPasseya
doi : 10.1016/S1474-4422(21)00385-9
Volume 20, Issue 12, December 2021, Page 977
Intracranial pressure monitoring and unfavourable outcomes
Randall MChesnuta
doi : 10.1016/S1474-4422(21)00371-9
Volume 20, Issue 12, December 2021, Page 978
Intracranial pressure monitoring and unfavourable outcomes
Leonardo CWellingaNicollas NunesRabelobcLeonardo LucaLucianodEberval GFigueiredob
doi : 10.1016/S1474-4422(21)00365-3
Volume 20, Issue 12, December 2021, Pages 978-979
Intracranial pressure monitoring and unfavourable outcomes – Authors' reply
GiuseppeCiterioaChiaraRobbaaFrancescaGrazianoaPaolaReboraa
doi : 10.1016/S1474-4422(21)00370-7
Volume 20, Issue 12, December 2021, Page 979
Overall fraction of disease attributable to multiple dependent risk factors: a new formula
IsabelleNiedhammeraJean-FrançoisChastanga
doi : 10.1016/S1474-4422(21)00366-5
Volume 20, Issue 12, December 2021, Pages 979-980
Safe laboratory management of prions and proteopathic seeds
SimonMeadaThomasEvansbAdvisory Committee for Dangerous Pathogens Transmissible Spongiform Encephalopathy Subgroup
doi : 10.1016/S1474-4422(21)00379-3
Volume 20, Issue 12, December 2021, Page 981
The East Asian Parkinson Disease Genomics Consortium
Kin YMokabc
doi : 10.1016/S1474-4422(21)00373-2
Volume 20, Issue 12, December 2021, Page 982
Correction to Lancet Neurol 2018; 17: 939–53
doi : 10.1016/S1474-4422(21)00382-3
Volume 20, Issue 12, December 2021, Page e7
Correction to Lancet Neurol 2018; 17: 954–76
doi : 10.1016/S1474-4422(21)00380-X
Volume 20, Issue 12, December 2021, Page e7
Correction to Lancet Neurol 2018; 17: 1061–82
doi : 10.1016/S1474-4422(21)00381-1
Volume 20, Issue 12, December 2021, Page e7
Correction to Lancet Neurol 2019; 18: 56–87
doi : 10.1016/S1474-4422(21)00383-5
Volume 20, Issue 12, December 2021, Page e7
Correction to Lancet Neurol 2021; 20: 1038–47
doi : 10.1016/S1474-4422(21)00390-2
Volume 20, Issue 12, December 2021, Page e7
Georgios Tsivgoulis: in top gear
AdrianBurton
doi : 10.1016/S1474-4422(21)00386-0
Volume 20, Issue 12, December 2021, Page 983
Trials for neurodegenerative diseases: time to innovate
Arpan RMehtaJeremyChatawaySuvankarPalMahesh K BParmarSiddharthanChandran
doi : 10.1016/S1474-4422(21)00388-4
Volume 20, Issue 12, December 2021, Page 984
The International Brain Initiative: enabling collaborative science
GianlucaQuaglioPatriziaToiaEdvard IMoserTheodorosKarapiperisKatrinAmuntsShigeoOkabeMu-mingPooJong-CheolRahYves DeKoninckJohnNgaiLindaRichardsJan GBjaalie
doi : 10.1016/S1474-4422(21)00389-6
Volume 20, Issue 12, December 2021, Pages 985-986
Lost in plain sight
EelcoWijdicks
doi : 10.1016/S1474-4422(21)00144-7
Volume 20, Issue 12, December 2021, Pages 987-988
Better buildings for elderly people to thrive
AineO'Connor
doi : 10.1016/S1474-4422(21)00337-9
Volume 20, Issue 12, December 2021, Pages 988-989
Supernova: remembering me as I was
JulesMorgan
doi : 10.1016/S1474-4422(21)00320-3
Volume 20, Issue 12, December 2021, Page 990
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study
ProfWolf ALagrèzeMDa*SebastianKüchlinMDa*GabrieleIhorstPhDbBirgitGrotejohannPhDbFlemmingBeisseMDdMartinVolkmannMDfSven PHeinrichPhDaProfPhilippAlbrechtMDgJudithUngewissPhDhMichaelWörnerPhDhiProfMartin JHugPhDcProfSebastianWolfMDjProfRicardaDiemMDek
doi : 10.1016/S1474-4422(21)00322-7
Volume 20, Issue 12, December 2021, Pages 991-1000
Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial
ProfTanujaChitnisMDaProfBrendaBanwellMDbcProfLudwigKapposMDdProfDouglas LArnoldMDefProfKivilcimGücüyenerMDgKumaranDeivaMDhProfNataliaSkripchenkoMDiProfLi-YingCuiMDjStephaneSaubaduMDkWenruoHuMPHlMyriamBenamorMDkAnnaigLe-HalperePharmDkPhilippeTruffinetMDkProfMarcTardieuMDh
doi : 10.1016/S1474-4422(21)00364-1
Volume 20, Issue 12, December 2021, Pages 1001-1011
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial
ProfJordiDiaz-ManeraMDabc*ProfPriya SKishnaniMDd*HaniKushlafMDeProfShafeeqLadhaMDfProfTahseenMozaffarMDgProfVolkerStraubMDaProfAntonioToscanoMDhProfAns Tvan der PloegMDiProfKenneth IBergerMDjkProfPaula RClemensMDlmYin-HsiuChienMDnProfJohn WDayMDoProfSergeyIllarioshkinMDpMarkRobertsMDqProfShahramAttarianMDrProfJoao LindolfoBorgesMDsFrancoiseBouhourMDtProfYoung ChulChoiMDuProfSevimErdem-OzdamarMDvOzlemGoker-AlpanMDwProfAnnaKostera-PruszczykMDxKristina AnHaackMDyChristopherHugMDzOlivierHuynh-BaMDaaJudithJohnsonMDzNathanThibaultPharmDzTianyueZhouPhDzProfMazen MDimachkieMDab†ProfBenediktSchoserMDac†on behalf of the
doi : 10.1016/S1474-4422(21)00241-6
Volume 20, Issue 12, December 2021, Pages 1012-1026
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial
ProfBenediktSchoserMDa*MarkRobertsMDb*Barry JByrneMDcSheelaSitaramanPhDdHaiJiangPhDdProfPascalLaforêtMDeProfAntonioToscanoMDfJeffCastelliPhDdProfJordiDíaz-ManeraMDgMitchellGoldmanMDdProfAns Tvan der PloegMDhDragoBratkovicMDiSrilakshmiKuchipudiMSdProfTahseenMozaffarMDj†ProfPriya SKishnaniMDk†
doi : 10.1016/S1474-4422(21)00331-8
Volume 20, Issue 12, December 2021, Pages 1027-1037
Neuromodulation in epilepsy: state-of-the-art approved therapies
ProfPhilippeRyvlinMDaProfSylvainRheimsMDbProfLawrence JHirschMDcArsenySokolovMDaProfLaraJehiMDd
doi : 10.1016/S1474-4422(21)00300-8
Volume 20, Issue 12, December 2021, Pages 1038-1047
Amantadine in the treatment of Parkinson's disease and other movement disorders
ProfOlivierRascolMDaMargheritaFabbriMDaProfWernerPoeweMDb
doi : 10.1016/S1474-4422(21)00249-0
Volume 20, Issue 12, December 2021, Pages 1048-1056
